---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-028916"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-08-25T20:12:59+00:00"
generated_at: "2026-08-25T20:14:10.818839+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vaxart creates two new board committees, appoints members

## Summary
- On Aug 21, 2026, board formed Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee.
- Dr. James B. Breitmeyer chairs Clinical/Regulatory; Dr. David Wheadon also appointed as member.
- W. Mark Watson named Interim Chair of Stockholder Engagement Committee; Steven Lo also a member.
- New director to chair Stockholder Engagement Committee per July 1, 2026 Cooperation Agreement.
- Committees oversee clinical/regulatory programs and stockholder relations respectively.

## SEC filing metadata
- accession: 0001437749-26-028916
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-08-25T20:12:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/0001437749-26-028916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/vxrt20260824_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-028916
- JSON: https://secwatch.observer/filing/0001437749-26-028916.json
- Plain text: https://secwatch.observer/filing/0001437749-26-028916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.